drugset
drugset / Trial / NCT05819775

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775 ↗

Phase 3 Completed 22 enrolled CSL Behring
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Timeline

Start
2023-05-30
Primary completion
2025-11-19
Completion
2025-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject CSL312 Monoclonal antibody — Subcutaneous

Indications

hereditary angioedema